Indivumed Therapeutics

SHAPING A FUTURE WITH INDIVIDUALIZED CANCER THERAPY

THE DEEP-DATA SOLUTION FOR NOVEL DISCOVERIES IN ONCOLOGY

With a focus on bioinformatics and multi-omics-based oncology R&D, we are your partner for biomarker and target discovery, drug development, and more. We enhance R&D activities and launch new discovery programs, providing expertise, capabilities, and insight throughout the whole development process. By unraveling the complex mechanisms of cancer, we shape the path toward precision oncology.

CLINICAL STANDARD

We are convinced that biospecimen and clinical data quality is crucial to making all relevant details of a cancer disease transparent. To ensure this, our partners in the Indivumed Global Clinical Network have implemented in-depth SOPs that have been developed and refined through decades of experience working side by side with surgeons and pathologists.

UNIQUE DATA AND SAMPLES

Following years of collaboration with our clinical partners, we can draw on a library of thousands of unique and complex high-quality datasets. These sets combine clinical and pathology data with genomics, transcriptomics, proteomics, and phosphoproteomics data. As the most comprehensive of its kind, the database constitutes an unparalleled resource with which to speed up discovery and development.

DATA-DRIVEN DISCOVERIES

Utilizing our unique datasets and our powerful discovery and validation platform nRavel®, we drive the discovery of new therapeutic drug targets, the assessment of molecular signaling pathways, and the identification of biomarkers and gene signatures for the stratification of cancer patients.

nRavel®
THE POWERFUL DISCOVERY PLATFORM

nRavel® Rx
TARGET IDENTIFICATION AND VALIDATION

PATIENT BASED TARGET DISCOVERY

Through combining multi-omic expression signatures and prognostic data in selected cohorts, we identify and validate new therapeutic drug targets in-silico that are further characterized and subsequently prioritized using the unique analytical power of nRavel®.

PATIENT BASED CELLULAR MODELS

Once a therapeutic drug target candidate has been successfully validated in-silico, the next step is to validate it in-vitro on 2D and 3D cell models derived from the original cohort used for the in-silico analyses.

nRavel® Dx
PRECISION CLINICAL TRIAL DESIGN

BIOMARKER BASED PATIENT SELECTION

Utilizing insights from the target discovery process and our clinical and multi-omics database, clinical trial design can be optimized for each investigative drug. Biomarkers based on these insights facilitate patient screening and stratification, and ultimately speed up the recruiting process.

MATCHED PATIENT CASES ACROSS THE DISCOVERY AND DEVELOPMENT PIPELINE

To achieve the most accurate results possible, end-to-end comparability is just as crucial as quality. That’s why we combine multi-omics data and deep clinical data with matched patient derived tumor models throughout our in-silico and in-vitro discovery workflows.

Indivumed Therapeutics

INDIVUMED THERAPEUTICS

Indivumed GmbH
Falkenried 88, Bldg. D
20251 Hamburg, Germany

Tel.: +49 (40) 41 33 83 0
Fax: +49 (40) 41 33 83 14
E-mail: info@indivumed.com
www.indivumed-therapeutics.com

05.2023